Pepaxti plus dexamethasone is intended to treat multiple myeloma patients who have received a minimum of three previous lines of treatment. Credit: KGH / Wikimedia.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Oncopeptides’ Pepaxti (melphalan flufenamide; melflufen) along with dexamethasone to treat multiple myeloma patients.

Pepaxti plus dexamethasone is intended to treat adult patients who have received a minimum of three previous lines of treatment.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The combination is indicated for usage in multiple myeloma patients whose disease is refractory to a minimum of one immunomodulatory agent, one proteasome inhibitor and one anti-CD38 monoclonal antibody, and has shown disease progression on or following the last treatment. 

In patients who have had autologous stem cell transplantation earlier, the time to progression should be a minimum of three years following transplantation.

The latest approval is based on the findings from the Phase II HORIZON clinical trial and is backed by results from the controlled, randomised Phase III OCEAN trial.

See Also:

In the Phase III LIGHTHOUSE trial, melflufen’s clinical benefit in patients with multiple myeloma was reported irrespective of their stem-cell transplant status.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Currently, the company is analysing Pepaxti’s market access options in the country.

A lipophilic peptide-conjugated alkylating drug, Pepaxti delivers cytotoxic agents into tumour cells. 

In August, the European Commission (EC) granted marketing authorisation for Pepaxti for usage in the EU, Norway, Iceland and Lichtenstein.

Oncopeptides CEO Jakob Lindberg said: “The approval of Pepaxti in the UK is one additional important milestone for Oncopeptides that further validates our science and data. 

“Pepaxti provides clinical benefit to patients with triple class refractory disease. This is very good news for patients with multiple myeloma, whose treatment options ultimately become exhausted.”